They are a blank check company. They will seek to identify, through the experience and expertise of their management team and board of directors, a biotech company that has demonstrated success and is primed to thrive in the rapidly evolving biotech industry. Their acquisition strategy is to leverage their expertise and network relationships to identify, negotiate and acquire one or more business targets (i.e. companies), and/or in-license one or more assets, or combine business targets with in-licensed assets with the ultimate objective of building a public clinical stage biotech enterprise. It is their goal to evaluate business targets that are developing or enabling development of pre-commercial therapeutic candidates across a broad array of therapeutic areas, with an initial focus on oncology and immunology. They have built their management team around the concept of combining individuals with extensive experience, varied backgrounds and skill sets. Their Chief Executive Officer, Sanjeev Satyal, has a proven and successful track record in the biotech industry and has robust operational experience. William McKeever, Chief Financial Officer, also brings a robust skill set that will complement those of their Chief Executive Officer. Mr. McKeever has more than twenty years of significant experience in the healthcare industry and has successfully held key positions in equity research, portfolio management and investment banking. As a result, Mr. McKeever, has broad experience in identifying attractive companies.